Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
// Jing Ma 1,2 , Yuan Gao 3 , Lin Jiang 1,2 , Feng-lei Chao 1,2 , Wei Huang 1,2 , Chun-ni Zhou 1,2 , Wei Tang 1,2 , Lei Zhang 1,2 , Chun-xia Huang 4 , Yi Zhang 1,2 , Yan-min Luo 1,2 , Qian Xiao 1,2 , Hua-rong Yu 4 , Rong Jiang 1,2 and Yong Tang 1,2 1 Department of Histology and Embryology, Chongqing Medical University, Chongqing, P. R. China 2 Laboratory of Stem Cells and Tissue Engineering, Chongqing Medical University, Chongqing, P. R. China 3 Department of Geriatrics, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P. R. China 4 Department of Physiology, Chongqing Medical University, Chongqing, P. R. China Correspondence to: Yong Tang, email: // Keywords : fluoxetine, Alzheimer’s disease, cognition, neuron, APP/PS1 mice, Gerotarget Received : July 04, 2016 Accepted : January 31, 2017 Published : February 16, 2017 Abstract Selective serotonin reuptake inhibitors (SSRIs) have been reported to increase cognitive performance in some clinical studies of Alzheimer’s disease (AD). However, there is a lack of evidence supporting the efficacy of SSRIs as cognition enhancers in AD, and the role of SSRIs as a treatment for AD remains largely unclear. Here, we characterized the impact of fluoxetine (FLX), a well-known SSRI, on neurons in the dentate gyrus (DG) and in CA1 and CA3 of the hippocampus of middle-aged (16 to 17 months old) APPswe/PSEN1dE9 (APP/PS1) transgenic AD model mice. We found that intraperitoneal (i.p.) injection of FLX (10 mg/kg/day) for 5 weeks effectively alleviated the impairment of spatial learning ability in middle-aged APP/PS1 mice as evaluated using the Morris water maze. More importantly, the number of neurons in the hippocampal DG was significantly increased by FLX. Additionally, FLX reduced the deposition of beta amyloid, inhibited GSK-3β activity and increased the level of β-catenin in middle-aged APP/PS1 mice. Collectively, the results of this study indicate that FLX delayed the progression of neuronal loss in the hippocampal DG in middle-aged AD mice, and this effect may underlie the FLX-induced improvement in learning ability. FLX may therefore serve as a promising therapeutic drug for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?
Deng, W., Aimone, J. B., & Gage, F. H. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2822 · Cited by 2,120 · cited 2×
“Several studies have shown that adult neurogenesis in the hippocampal DG stimulates hippocampal function and introduces the possibility of a new form of hippocampal plasticity, especially hippocampus-dependent learning and memory [83, 84, 86, 87].”
BackgroundWNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“Whether reducing beta amyloid is beneficial to the pathogenesis of AD remains controversial, given that several lines of evidence have revealed that drugs targeting to clear the beta amyloid protein plaques fail to improve cognition in AD patients and may even result in terrible side effects, such as skin cancer [69,…”
BackgroundA Functional Role for Adult Hippocampal Neurogenesis in Spatial Pattern Separation
Clelland, C. D., Choi, M., Romberg, C., Clemenson, G. D., Fragniere, A., Tyers, P., Jessberger, S., Saksida, L. M., Barker, R. A., Gage, F. H., et al. (2009) · Science · doi:10.1126/science.1173215 · Cited by 1,642
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“Moreover, hippocampal neuron loss has been reported to exceed the amyloid deposits and the neurofibrillary tangles in the transgenic mouse model of AD or in patients with AD [5, 6].”
BackgroundThe efficiency of systematic sampling in stereology—reconsidered
GUNDERSEN, H. J. G., JENSEN, E. B. V., KIÊU, K., & NIELSEN, J. (1999) · Journal of Microscopy · doi:10.1046/j.1365-2818.1999.00457.x · Cited by 1,317 · cited 1×
“The coefficient of error (CE) estimates were determined according to Gundersen et al [111].”
MethodDifferences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
West, M. J., Coleman, P. D., Flood, D. G., & Troncoso, J. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92338-8 · Cited by 1,267 · cited 1×
“The decrease in the numbers of neurons in CA1 and DG is in agreement with previous studies reporting neuronal loss in CA1 [74-78] and DG [1, 77, 78] in AD.”
ResultA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 1×
“Although several drugs have been approved for the clinical treatment of AD [13], these drugs activate cholinergic or suppress glutamatergic neurotransmission and therefore improve only the symptoms of AD.”
Sairanen, M., Lucas, G., Ernfors, P., Castrén, M., & Castrén, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3741-04.2005 · Cited by 763 · cited 1×
“com/oncotarget been applied in several previous reports [24, 60-65].”
Method
Cited by
Depression, dementia and immune dysregulation
Hayley, S., Hakim, A. M., & Albert, P. R. (2021) · Brain · doi:10.1093/brain/awaa405 · Cited by 186
Hill, M. A., & Gammie, S. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-22179-z · Cited by 56
Zhang, J., Wu, N., Wang, S., Yao, Z., Xiao, F., Lu, J., & Chen, B. (2021) · Aging Cell · doi:10.1111/acel.13380 · Cited by 33
“The results of these experiments showed that NeuN- positive neuron loss was restricted to the core area of both large and small Aβ deposits in 12- month- old APPswe/PSEN1dE9 mice (Figure S4).”
BackgroundInfluentialQin, M., Wu, J., Zhou, Q., Liang, Z., & Su, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.039 · Cited by 12
Metadata
- Authors
- Ma, J., Gao, Y., Jiang, L., Chao, F.-L., Huang, W., Zhou, C.-N., Tang, W., Zhang, L., Huang, C.-X., Zhang, Y., Luo, Y.-M., Xiao, Q., Yu, H.-R., Jiang, R., & Tang, Y.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-16
- Volume
- 8
- Issue
- 17
- Pages
- 27676-27692
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2590078180
- Cited by
- 51
- References
- 31
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.